BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.

• Phase: Phase 2

Details

• Lead Sponsor: Dongzhimen Hospital, Beijing
• Collaborators: Beijing Chuanglikechuang Medical Technology Development Co., Ltd.; Hunan Academy of Traditional Chinese Medicine Affiliated Hospital; Jiangbin Hospital of Guangxi Zhuang Autonomous Region; Rizhao Hospital of Traditional Chinese Medicine; Shaanxi Buchang Pharmaceuticals Co., Ltd.; Shanghai Youningwei Biotechnology Co., Ltd.; The Affiliated Hospital of Changchun University of Chinese Medicine; The Affiliated Hospital of Chengdu University of Chinese Medicine; The Affiliated Hospital of Shandong University of Chinese Medicine; The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine; The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine; The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine; The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine; The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine; The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Wuhan Third Hospital; Wuhan Zhizhi Medical Technology Co., Ltd.